1093.HK - CSPC Pharmaceutical Group Limited

HKSE - HKSE Delayed Price. Currency in HKD
23.650
-0.100 (-0.42%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close23.750
Open23.850
Bid23.650 x 0
Ask23.750 x 0
Day's Range23.300 - 23.950
52 Week Range10.940 - 26.750
Volume20,694,365
Avg. Volume34,080,203
Market Cap147.647B
Beta0.75
PE Ratio (TTM)52.00
EPS (TTM)0.455
Earnings DateMay 23, 2018 - May 28, 2018
Forward Dividend & Yield0.15 (0.62%)
Ex-Dividend Date2018-05-30
1y Target Est25.69
  • The Wall Street Journal9 days ago

    [$$] Court Revives Price-Fixing Case Against Chinese Vitamin C Makers

    WASHINGTON—The Supreme Court revived a price-fixing case against Chinese vitamin C makers Thursday, ruling a lower court was too deferential to arguments by the Chinese government in defense of its companies. The case raised delicate political, economic and legal questions, and pitted the Trump administration against China. The litigation dates to 2005, when vitamin C purchasers, including a Texas animal-feed company and a New Jersey vitamin distributor, alleged that Chinese vitamin manufacturers conspired to fix prices and supplies in the U.S.

  • Does CSPC Pharmaceutical Group Limited’s (HKG:1093) Recent Track Record Look Strong?
    Simply Wall St.18 days ago

    Does CSPC Pharmaceutical Group Limited’s (HKG:1093) Recent Track Record Look Strong?

    Assessing CSPC Pharmaceutical Group Limited’s (SEHK:1093) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense checkRead More...

  • China Drugmaker's 65% Rally Just Start for Bullish Analysts
    Bloomberg27 days ago

    China Drugmaker's 65% Rally Just Start for Bullish Analysts

    China’s top-performing drugmaker stock may be about to head even higher. At least eight brokers lifted their price targets on CSPC Pharmaceutical Group Ltd. after the company reported a 43 percent surge in first-quarter profit on Friday. The result beat the market’s already high expectations, according to Credit Suisse Group AG, which raised its target by 24 percent -- the most bullish among analysts tracked by Bloomberg.

  • Bloomberg27 days ago

    China Drugmaker's 65% Rally Just the Start for Bullish Analysts

    China’s top-performing drugmaker stock may be about to head even higher. At least eight brokers lifted their price targets on CSPC Pharmaceutical Group Ltd. after the company reported a 43 percent surge in first-quarter profit on Friday. The result beat the market’s already high expectations, according to Credit Suisse Group AG, which raised its target by 24 percent -- the most bullish among analysts tracked by Bloomberg.

  • Reuterslast month

    BRIEF-CSPC Pharmaceutical Group Appoints Wang Zhenguo as Vice-Chairman And Rotating CEO

    May 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * PAN WEIDONG CEASED AS ROTATING CHIEF EXECUTIVE OFFICER * WANG ZHENGUO HAS BEEN APPOINTED AS VICE-CHAIRMAN AND ROTATING CHIEF EXECUTIVE OFFICER * PAN ...

  • Reuterslast month

    BRIEF-CSPC Pharmaceutical Group Posts Qtrly Profit Attributable Of HK$909.9 Mln

    May 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * QTRLY PROFIT ATTRIBUTABLE HK$909.9 MILLION VERSUS HK$637.9 MILLION * QTRLY TOTAL REVENUE HK$5.39 BILLION VERSUS HK$3.47 BILLION Source text for Eikon: ...

  • Reuterslast month

    BRIEF-CSPC Pharmaceutical Group Says Qimaite Drug Granted Approval By China Food And Drug Administration

    May 21 (Reuters) - CSPC Pharmaceutical Group Ltd: * GROUP'S "QIMAITE" GRANTED APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:

  • Reuterslast month

    BRIEF-CSPC Pharmaceutical Group Updates on Drug Registration Approval For Injection By China FDA

    May 10 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC PHARMACEUTICAL GROUP-"DOXOFYLLINE GLUCOSE FOR INJECTION" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FDA * "DOXOFYLLINE SODIUM CHLORIDE ...

  • Have Investors Priced In CSPC Pharmaceutical Group Limited’s (HKG:1093) Growth?
    Simply Wall St.2 months ago

    Have Investors Priced In CSPC Pharmaceutical Group Limited’s (HKG:1093) Growth?

    Let’s talk about the popular CSPC Pharmaceutical Group Limited (SEHK:1093). The company’s shares saw a significant share price rise of over 20% in the past couple of months on theRead More...

  • The Wall Street Journal2 months ago

    [$$] Supreme Court Weighs Price-Fixing Case Against Chinese Vitamin C Makers

    WASHINGTON—The Trump administration and the Chinese government squared off Tuesday at the Supreme Court in a price-fixing case that raised questions about how U.S. judges should consider legal submissions by foreign governments. The case centers on a lawsuit by vitamin C purchasers, including a Texas animal-feed company and a New Jersey vitamin distributor, that alleged Chinese manufacturers of vitamin C conspired to fix prices and supplies in the U.S. The Chinese government took the unusual step of filing papers in U.S. courts, saying the companies shouldn’t be penalized because their practices were indeed mandated by state industrial regulation.

  • Reuters2 months ago

    BRIEF-CSPC Pharmaceutical Announces A Product Licensing Agreement

    April 18 (Reuters) - CSPC Pharmaceutical Group Ltd : * UNIT ENTERED PRODUCT LICENSING AGREEMENT WITH GALAXY BIO, INC. FOR LICENSING & COMMERCIALIZATION OF "PACLITAXEL FOR INJECTION" * GALAXY ...

  • Reuters2 months ago

    BRIEF-CSPC Pharmaceutical Group Says Cancer Drug Approved By China FDA

    April 16 (Reuters) - CSPC Pharmaceutical Group Ltd : * "VINORELBINE TARTRATE LIPOSOME INJECTION" GRANTED CLINICAL TRIAL APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION OF PRC Source text for Eikon: ...

  • Reuters2 months ago

    BRIEF-CSPC Pharmaceutical Group's Drug Gets Approval By China FDA

    April 12 (Reuters) - CSPC Pharmaceutical Group Ltd : * GRANTED APPROVAL BY CHINA FDA FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY EVALUATION OF GENERIC DRUGS * APPROVAL FOR GROUP'S DRUG "WEIHONG" ...

  • PR Newswire3 months ago

    CSPC Pharmaceutical Announces 2017 Annual Results

    HONG KONG, March 19, 2018 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (1093.HK) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company in China, is pleased to announce its annual results for the Year ended 31 December 2017 (the "Year"). With the Group's continuous efforts of academic promotion and market development, coupled with the gradual implementation of the new tender results and the inclusion of "NBP" injection and "Jinyouli" into the new National Reimbursement Drug List (the "New NRDL"), the innovative drug products continued its robust growth, along with further expansion of market share. Sales of innovative drug products for the Year reached approximately HK$6,582 million, representing a 37.9% growth year-on-year.

  • Reuters3 months ago

    BRIEF-CSPC Pharmaceutical Group Says FY Profit Attributable HK$2.77 Bln

    March 19 (Reuters) - Cspc Pharmaceutical Group Ltd : * FY REVENUE HK$ ‍15.46​ BILLION VERSUS HK$12.37 BILLION * FY PROFIT ATTRIBUTABLE HK$2.77 BILLION VERSUS HK$2.10 BILLION * ‍FINAL DIVIDEND PER SHARE ...

  • Reuters3 months ago

    BRIEF-CSPC Pharmaceutical Group Says ‍Cancer Drug Granted Drug Clinical Trial Approval By China FDA

    March 16 (Reuters) - CSPC Pharmaceutical Group Ltd : * ‍CANCER DRUG DEVELOPED BY WUHAN YZY BIOPHARMA​ GRANTED DRUG CLINICAL TRIAL APPROVAL BY CHINA FDA Source text for Eikon: Further company coverage:

  • Best High Growth SEHK Stocks This Week
    Simply Wall St.3 months ago

    Best High Growth SEHK Stocks This Week

    Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Minsheng Education Group and ANTA Sports Products are deemed toRead More...

  • Is CSPC Pharmaceutical Group Limited’s (HKG:1093) PE Ratio A Signal To Sell For Investors?
    Simply Wall St.4 months ago

    Is CSPC Pharmaceutical Group Limited’s (HKG:1093) PE Ratio A Signal To Sell For Investors?

    CSPC Pharmaceutical Group Limited (SEHK:1093) trades with a trailing P/E of 41.7x, which is higher than the industry average of 18.3x. While 1093 might seem like a stock to avoidRead More...

  • Reuters4 months ago

    BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"

    Feb 12 (Reuters) - CSPC Pharmaceutical Group Ltd: * ‍"PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: ...

  • ANTA Sports Products And Other Top Growth Stocks
    Simply Wall St.4 months ago

    ANTA Sports Products And Other Top Growth Stocks

    ANTA Sports Products and Hong Kong Exchanges and Clearing can add profound upside to your portfolio. This is because the optimistic growth outlook for their profitability and returns make theirRead More...

  • What does CSPC Pharmaceutical Group Limited’s (HKG:1093) Balance Sheet Tell Us About Its Future?
    Simply Wall St.4 months ago

    What does CSPC Pharmaceutical Group Limited’s (HKG:1093) Balance Sheet Tell Us About Its Future?

    The size of CSPC Pharmaceutical Group Limited (SEHK:1093), a HK$100.01B large-cap, often attracts investors seeking a reliable investment in the stock market. One reason being its ‘too big to fail’Read More...

  • Reuters5 months ago

    Tencent, China Mobile to join Hang Seng China Enterprises Index

    HONG KONG, Feb 6 (Reuters) - Hong Kong's stock index compiler said on Tuesday that a total of ten Red-chips and P-chips, including Tencent, CITIC Ltd and China Mobile Ltd, have been selected to join the ...

  • Reuters5 months ago

    BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​

    Feb 6 (Reuters) - CSPC Pharmaceutical Group Ltd: * ‍GROUP'S GASTRIC CANCER DRUG "DP303C" WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA​ Source text for Eikon: Further company coverage:

  • Best Growth Stock in January
    Simply Wall St.5 months ago

    Best Growth Stock in January

    Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as CSPC Pharmaceutical Group and ANTA Sports Products are considered to be high growthRead More...